* Nuvectis Pharma Inc reported a quarterly adjusted loss of 25 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of three analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -40 cents to -39 cents per share.
* Reported revenue was zero; analysts expected zero.
* Nuvectis Pharma Inc's reported EPS for the quarter was a loss of 25 cents.
* The company reported a quarterly loss of $4.17 million.
* Nuvectis Pharma Inc shares had fallen by 7.8% this quarter and lost 9.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 7.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Nuvectis Pharma Inc is $21.00 This summary was machine generated from LSEG data May 7 at 01:46 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.40 -0.25 Beat
Dec. 31 2023 -0.36 -0.41 Missed
Sep. 30 2023 -0.34 -0.37 Missed
Jun. 30 2023 -0.29 -0.38 Missed
Comments